



For Immediate Release

November 1, 2017

VALENS GROWORKS ADDED TO CSE25 INDEX

Vancouver, B.C., November 1, 2017 – Valens GroWorks Corp. (CSE: VGW) (the “Company” or “Valens”), a biotechnology company specializing in the production, research, development and commercialization of novel, cannabinoid-based products and drug therapies, is pleased to announce its inclusion in the CSE25 Index. The CSE25 Index is a subgroup of the CSE Composite Index that recognizes the highest achievers listed on the CSE. Valens qualified for the index as one of the twenty-five largest companies in the CSE Composite Index.

About the CSE25 Index

The Canadian Securities Exchange (“CSE”) recently announced the introduction of the CSE25 Index, comprised of the securities of the largest companies trading on the exchange. The CSE25 Index is a subgroup of the CSE Composite Index. The composite index launched in 2015 and includes almost half of the exchange's listed companies and, according to the CSE, covers over 75% of the trading activity on the exchange. The new index includes the top twenty-five securities by market capitalization contained in the composite index. According to the CSE, these companies account for over 50% of the weighting in the larger index and are typically stocks that attract considerable trading volume.

About Valens GroWorks Corp.

Valens GroWorks Corp. is a biotechnology company with an aggressive buildout strategy. The Company seeks to capture a broad spectrum of medical cannabis users, and adult recreational users once legalized, as well as clinical trial and R&D clients, in pursuit of its ambitious “*plants to premium products*” objectives.

The Company operates a 17,000 square foot facility located on two acres in Kelowna, in the heart of British Columbia’s Okanagan Valley. Wholly owned subsidiary Supra THC Services Inc. (“Supra”), in collaboration with Thermo Fisher Scientific, a world leader in Health Science services, is developing a “Centre of Excellence in Plant Based Medicine Analytics” to provide analytical services and directed research and development, including clinical trials. Supra and the Company’s subsidiary Valens AgriTech Ltd. (“Valens AgriTech”), a Health Canada Licensed Dealer, recently announced a \$330,000 MITACS funded research grant and collaboration with UBC Okanagan and Thompson Rivers University to explore potential cannabis bio-products including pharmaceuticals, nutritional products, and industrial fiber.

For more information, visit www.valensgroworks.com

**On behalf of the Board of Directors,
VALENS GROWORKS CORP.**

(signed) “Robert van Santen”
Chief Financial Officer

For further information, please contact:

Greg Patchell
Telephone: +1.250.860.8634

Notice regarding Forward Looking Statements

Valens GroWorks Corp.
14th Floor, 1040 West Georgia Street,
Vancouver, British Columbia, Canada V6E 4H1
T. 604.608.1999 F. 788.379.9990
www.valensgroworks.com



This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Corporation is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither the CSE nor its regulations services provider have reviewed, approved or accept responsibility for the adequacy or accuracy of this press release. We seek Safe Harbour.